Key presentations at the recent 93rd Congress of the European Atherosclerosis Society (4-7 May 2025, Glasgow, UK) included a comprehensive review of clinical trials of novel TG-lowering agents, study updates for olezarsen, plozasiran and zodasiran, initial findings with the novel ANGPTL4 antibody, MAR001, and fresh insights on the impact of an ANGPTL3 loss of function variant on kidney disease risk.
Read the reports:
- Where are we up to with TG lowering?
- All-day TG lowering with olezarsen linked to reduced inflammatory risk
- PALISADE trial shows QoL benefits with plozasiran
- Final GATEWAY study results confirm lipid lowering with zodasiran
- ANGPTL4 antibody reduces TG and remnant cholesterol
- ANGPTL3 variant protects against kidney disease
Reporting by Jenny Bryan
